Checkpoint Therapeutics rises on seeking FDA approval for skin cancer drug

Checkpoint Therapeutics

04/01/2023 15:13

** Shares of drug developer Checkpoint Therapeutics Inc
 CKPT.O  jump 9.6% to $6.73
    ** Company submits marketing application to the U.S. FDA for
its investigational antibody drug cosibelimab as a treatment for
cutaneous squamous cell carcinoma, the second most common type
of skin cancer in the United States
    ** The medication targets cancer patients who are not
candidates for curative surgery or radiation therapy
    ** Submission is based on positive efficacy and safety
results from ongoing clinical trial evaluating cosibelimab in
fixed doses of either 800 mg every two weeks or 1200 mg every
three weeks in patients - CKPT
    ** The drug met the main goal of inducing partial or
complete response in 47.4% of patients in a trial in 2022,
company says
    ** Company's shares fell 83.6% in 2022
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))